Similar articles

• Effect of chronic angiotensin II type I receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic variables in patients with heart failure.

  Davie AP, Rumley A, Lowe GD, McMurray JJ. Davie AP, et al. Thromb Haemost. 2001 Dec;86(6):1585-6. Thromb Haemost. 2001. PMID: 11776334 Clinical Trial. No abstract available.
• Angiotensin-converting enzyme inhibition facilitates alveolar-capillary gas transfer and improves ventilation-perfusion coupling in patients with left ventricular dysfunction.

  Guazzi M, Melzi G, Marenzi GC, Agostoni P. Guazzi M, et al. Clin Pharmacol Ther. 1999 Mar;65(3):319-27. doi: 10.1016/S0009-9236(99)70111-6. Clin Pharmacol Ther. 1999. PMID: 10096264
• Left ventricular function and response to enalapril in patients with Duchenne muscular dystrophy during the second decade of life.

  Giglio V. Giglio V. Am J Cardiol. 2007 Jan 1;99(1):147-8. doi: 10.1016/j.amjcard.2006.10.008. Epub 2006 Nov 29. Am J Cardiol. 2007. PMID: 17196482 No abstract available.
• Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study.

  Tsuyuki RT, Yusuf S, Rouleau JL, Maggioni AP, McKelvie RS, Wiecek EM, Wang Y, Pogue J, Teo KK, White M, Avezum A Jr, Latini R, Held P, Lindgren E, Probstfield J. Tsuyuki RT, et al. Can J Cardiol. 1997 Dec;13(12):1166-74. Can J Cardiol. 1997. PMID: 9444298 Review.
• Should angiotensin receptor blockers be added to angiotensin-converting enzyme inhibitors in the treatment of heart failure?

  Ghanem FA, Movahed A. Ghanem FA, et al. Rev Cardiovasc Med. 2005 Fall;6(4):206-13. Rev Cardiovasc Med. 2005. PMID: 16379016 Review.